BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.14B |
| Revenue (ttm) | 32.05M |
| Net Income (ttm) | -209.50M |
| Shares Out | 177.34M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $11.96 |
| Previous Close | $12.49 |
| Change ($) | -0.53 |
| Change (%) | -4.24% |
| Day's Open | 12.51 |
| Day's Range | 11.84 - 12.61 |
| Day's Volume | 3,142,429 |
| 52-Week Range | 3.30 - 14.24 |
RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency...
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a first-quarter loss of $0.36, wider than the consensus loss of $0.27 and deeper than the EPS loss of $0.24 reported a year ago mainly driven by high...
The drugmaker reported better-than-expected Q1 results.
BioCryst (BCRX) delivered earnings and revenue surprises of -38.46% and 48.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
—Q1 2021 ORLADEYO ™ (berotralstat) net revenue of $10.9 million—
RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO™ (...
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Th...
Investors cheered good news out of Japan for the company's lead product.
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan—
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare ...
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an...
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an ...
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...
RESEARCH TRIANGLE PARK, N.C., March 19, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly crea...
For investors and media only
With the trading day about halfway over, the broad markets came roaring back to start out the week.
The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralstat) for ro...
The company's fourth-quarter earnings report did not pass muster.
BioCryst (BCRX) delivered earnings and revenue surprises of -36.00% and -72.72%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial...
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 2021 American...
In less than several weeks, BioCryst Pharmaceuticals (NASDAQ: BCRX) shares have advanced from $7.2 above $12, and the current price stands around $10.2. According to the latest news, the FDA approved Ra...
Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical trials of...
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenz...
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental...
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares, which had been locked in a trading range since the start of January, broke out of the range Monday and rallied strongly, only to pull back in the ne...
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted sev...
BioCryst Pharmaceuticals surged 39% to a five-year high on Monday as Reddit investors declared a "BioWar" against short-sellers betting against the stock. The move followed a post on the r/WallStreetBet...
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...
RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted m...
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 ...
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conf...
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
Both stocks are in the early stage of a long-term growth trajectory.
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.
Investors were disappointed by the biotech's COVID-19 clinical trial results.
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, ga...
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like...
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...
—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care —
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which...
BioCryst received FDA approval for Orladeyo last week. The company quickly moved to raise cash and remove the financing overhang.
BioCryst (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has received a price target increase from $13 to $14 by H.C. Wainwright.
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial ... [Read more...]
| Industry Biotechnology | IPO Date Mar 3, 1994 |
| CEO Jon Stonehouse | Employees 246 |
| Stock Exchange NASDAQ | Ticker Symbol BCRX |
Financial Performance
In 2020, BCRX's revenue was $17.81 million, a decrease of -63.53% compared to the previous year's $48.84 million. Losses were -$182.81 million, 67.9% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 16.56, which is an increase of 38.46% from the latest price.